Nexentis Technologies Inc. (formerly N2OFF, Inc.) reported a significant financial performance shift in its latest quarterly filing, revealing a net loss of $6.6 million for the three months ended March 31, 2026, compared to a loss of $1.3 million during the same period in 2025. The increase in net loss is primarily attributed to a non-cash goodwill impairment of $6.3 million related to its MitoCareX reporting unit, which was acquired in October 2025. The company's total revenue for the quarter was $60,000, a slight decrease from $66,000 in the previous year, reflecting ongoing challenges in its operations.
The company’s operating expenses surged to $8.2 million, up from $503,000 in the prior year, driven by increased research and development costs following the acquisition of MitoCareX, as well as higher general and administrative expenses, which rose to $1.9 million from $503,000. The substantial rise in expenses is linked to share-based compensation and professional services associated with the integration of MitoCareX into the company's operations. Additionally, the company recognized a gain of $343,000 from the change in fair value of contingent consideration related to the MitoCareX acquisition.
Nexentis has undergone significant strategic changes, including the divestiture of its Save Foods Ltd. subsidiary, which was completed on March 15, 2026. This transaction resulted in a gain of $880,000 from discontinued operations, marking a notable improvement compared to the loss of $141,000 reported in the same quarter of the previous year. The company now focuses on its biotechnology and renewable energy segments, with MitoCareX developing oncology therapeutics and NITO Renewable Energy, Inc. engaging in solar energy projects across Europe.
Operationally, Nexentis reported cash and cash equivalents of $4.3 million as of March 31, 2026, an increase from $2.7 million a year earlier. The company’s working capital also improved to $6.5 million, up from $3.4 million, indicating a stronger liquidity position. However, the company continues to face challenges, including geopolitical risks affecting its operations in Israel and the need for additional financing to support its growth initiatives. Management has expressed concerns about its ability to continue as a going concern beyond the first quarter of 2027 without securing further capital.
Looking ahead, Nexentis plans to continue its focus on developing innovative oncology solutions through MitoCareX while expanding its renewable energy projects in collaboration with Solterra Renewable Energy Ltd. The company aims to leverage its proprietary MITOLINE™ algorithm for drug discovery and is exploring additional investment opportunities in the solar energy sector. However, the ongoing geopolitical instability in the region poses risks that could impact its operational capabilities and financial performance.
About N2OFF, Inc.
N2OFF, Inc. develops eco-friendly post-harvest and pre-harvest solutions for the agri-food industry, focusing on food safety and reducing food waste. Its core products include proprietary blends of organic acids and sanitizers that control pathogens, extend shelf life, and meet strict regulatory standards. Serving global markets, the company partners with packers, growers, and distributors to promote sustainable, chemical-residue-free produce.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.